Biomarker Research

 
News Articles for Biomarker Research top ^
2014/3/11
SHANGHAI and SEATTLE , March 11, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) , a leading pharmaceutical, biotechnology and medical device R&D services company with operations in China and the United States , and Pacific Biomarkers (PBI), a premier biomarker laboratory services provider based in Seattle , today announced a biomarker collaboration.
Sign-up for WuXi PharmaTech and Pacific Biomarkers Announce Collaboration investment picks
Fluidigm and Olink Bioscience have teamed up to enable interrogation of 96 samples across 92 proteins in a single run from one microliter of sample in less than a day.
Sign-up for Fluidigm and Olink Bioscience Bring a New Level of Protein Biomarker Discovery to the Life Science Research Market investment picks
2014/3/10
WALTHAM, Mass., March 10, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that galectin-3 testing has been recognized for the first time in the newly issued 2014 Indian Consensus Document on Cardiac Biomarkers published by the Cardiological Society of India.
Sign-up for BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers investment picks
2013/9/24
Quintiles today announced plans to improve the development of biomarker-targeted therapies through a novel approach that promotes the genomic “pre-profiling” of cancer patients.
Sign-up for Quintiles Advances New Approach to Speed Biomarker-Targeted Therapies to Cancer Patients investment picks
2014/4/10
HILDEN , Germany and VIENNA , April 10, 2014 /PRNewswire/ --  Reliable diagnostic tools under development for mutations of calreticulin (CALR) are expected to benefit patients with blood disorders known as myeloproliferative neoplasms   QIAGEN acquired exclusive worldwide license for CALR biomarker from CeMM Vienna, whose researchers recently published the discovery in the   New England Journal of Medicine   Addition of CALR biomarker expands market-leading position in Personalized Healthcare in blood disorders, which includes JAK2, BCR-ABL and other assays   QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has acquired an exclusive worldwide license to the biomarker calreticulin (CALR), whose recently discovered mutations are found in an estimated 15% of cases of myeloproliferative neoplasms (MPNs), a group of blood disorders.
Sign-up for QIAGEN Adds Promising New Biomarker to Pipeline of Personalized Healthcare Assays to Improve Diagnosis of Blood Disorders investment picks
Study Links RAS Mutations to Vectibix Clinical Response in Patients With Metastatic Colorectal Cancer THOUSAND OAKS, Calif.
Sign-up for Analysis Published In New England Journal of Medicine Highlights Discovery Of New Predictive Biomarkers For Vectibix® (Panitumumab) investment picks
Oncolytics Biotech® Inc. Collaborators Present Positive Data Correlating Specific Biomarkers with Survival in NSCLC Patients Treated with REOLYSIN®, Carboplatin and Paclitaxel Canada NewsWire About Lung Cancer The American Cancer Society estimates that in 2013, approximately 228,190 new cases of lung cancer will be diagnosed.
Sign-up for Oncolytics Biotech® Inc. Collaborators Present Positive Data Correlating Specific Biomarkers with Survival in NSCLC Patients Treated with REOLYSIN®, Carboplatin and Paclitaxel investment picks
2013/12/31
Following the Successful Utilization of A3 Adenosine Receptor Biomarker in Can-Fite's Phase IIb Rheumatoid Arthritis Study PETACH TIKVA, Israel , Dec.
Sign-up for OphthaliX to Retrospectively Analyze Phase III Dry Eye Syndrome Study Data Based on A3 Adenosine Receptor Biomarker investment picks
2014/1/13
-Regulus microMarkers™ Designed to Support Regulus' Therapeutic Pipeline, its Collaborators and Strategic Partners- LA JOLLA, Calif.
Sign-up for Regulus Expands its Biomarkers Platform and Establishes Regulus microMarkers™, a New R&D Division Focused on Identifying microRNAs as Biomarkers of Disease investment picks
2014/1/13
GERMANTOWN, Maryland , and HILDEN, Germany , January 13, 2014 /PRNewswire/ -- Expanding collaboration to develop FDA-regulated diagnostics based on exosomes to measure gene mutations targeted by new anti-cancer therapies Non-invasive detection of biomarkers from blood reduces patient risk and advances access to the benefits of personalized medicine Automated biofluid-based molecular diagnostics have significant potential to replace many costly and invasive tissue biopsies and add new testing options QIAGEN set to launch during 2014 the first in a series of new sample preparation kits for processing nucleic acids from biofluid exosomes QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced an expansion of its strategic partnership with Exosome Diagnostics Inc. to develop a first-in-class, non-invasive molecular in-vitro diagnostics for use in diagnosing and
Sign-up for QIAGEN and Exosome Diagnostics to Develop First-In-Class, Non-Invasive Diagnostics for Key Genetic Biomarkers in Lung and Other Cancers investment picks
2014/2/24
TEL AVIV, Israel, Feb.
Sign-up for Alcobra Ltd. to Discuss Biomarkers in Fragile X and Autism Trials at the Second Annual Autism Investment Conference investment picks
2014/3/31
GR-MD-02 was safe and well tolerated in patients Galectin Therapeutics to host webcast, April 1, 8:30 a.m. EDT to discuss first cohort findings Second cohort of Phase 1 trial to begin enrollment in April NORCROSS, Ga., March 31, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that results from the first cohort of its Phase 1 trial show that GR-MD-02 had an effect on biomarkers that suggest a therapeutic effect on fibrosis, inflammation, and cellular injury.
Sign-up for First Cohort Results in Galectin Therapeutics' Phase 1 Trial Reveal Biomarker Evidence of Therapeutic Effect on Fibrosis and Inflammation in NASH With Advanced Fibrosis investment picks
2013/8/8
Believed to be first clinical test to identify variants of four enzymes that mediate drug metabolism, providing greater insights for guiding treatment for the more than 100 million Americans with chronic pain MADISON, N.J. , Aug.
Sign-up for Quest Diagnostics Introduces Comprehensive Opioid Therapy Genetic Test Based on CYP450 Biomarker License with Transgenomic investment picks
2014/1/21
NORCROSS, Ga., Jan.
Sign-up for Preclinical Study Demonstrates Effect of Galectin Inhibitor on Serum Biomarker in Fatty Liver Disease With Fibrosis investment picks
2014/1/27
-  Improved Cognitive Function and Social Interaction Correlated With Changes in Blood Levels of Fragile X-Specific Molecular Targets -  Clinical Study With MG01CI in Fragile X Syndrome Planned for 2014 TEL AVIV, Israel, Jan.
Sign-up for Alcobra Announces New Biomarker Finding in a Follow-Up Fragile X Animal Study for MG01CI investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Biomarker Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Biofuel Energy  |  Next: Biomedical Companies